Sarossa Share Discussion Threads

[callumross] 30/9/2014 16:35

Just noticed this re GVC options: Nice £1m profit for no outlay with GVC shares trading at £5 today!

GVC Holdings PLC (AIM:GVC), the multinational sports betting and gaming group, announces the exercise of 343,053 share options (the "Options") by Sarossa Capital Limited (previously known as Antisoma plc).
As disclosed in the Company's prospectus dated 25 January 2013, GVC granted, or agreed to grant Antisoma plc options over a total of 343,053 ordinary shares of €0.01 par value each in the capital of the Company ("Ordinary Shares"), pursuant to GVC's acquisition of Sportingbet plc, which completed in March 2013. The Options were granted at market price on the date of their respective grants, but with a dividend credit mechanism which adjusted the Options' exercise prices relative to all dividends declared by GVC from the date of the grants up until exercise. The Options' average exercise price is therefore approximately £1.89 per share.

[callumross] 30/9/2014 08:43

Very solid results. 2.65p per share net assets, including 1p per share net cash. Looks good value at these levels IMHO, especially with the Richard Griffiths connection.

[praipus] 02/7/2014 17:04

Thanks for thread andrbea:)

Any chance of chucking this in the header for ease of access?


I follow other Richard Griffiths holdings on the WAM thread

[andrbea] 21/5/2014 17:27

returning to float price

[andrbea] 21/5/2014 17:26

principal activity : investment in and growth and development of portfolio businesses which present opportunities for value creation

[scratchi] 07/4/2009 08:09

Bird flu is the one to worry about, I know for a fact that some Doctors have stocked up on Tamiflu, they wouldn't do that if the threat wasn't real.
Hyper Al, you have been around for years, good to see the market hasn't emptied your trading pot over the last 7 or so years!

[waldron] 07/8/2005 11:42

China approves human trials for new SARS vaccine - reports
BEIJING (AFX) - China has given approval for a new vaccine for the
pneumonia-like disease Severe Acute Respiratory Syndrome (SARS) to go through
human trials, state-run media reported.
The vaccine, developed by a Beijing-based inspection and quarantine body,
was created in October and is undergoing clinical trials, the China Daily said.
Tests on monkeys at Wuhan University in central China's Hubei province
proved successful, the newspaper cited an official with the Beijing Entry-Exit
Inspection and Quarantine Bureau as saying.
The official said antibodies were found in the animals injected with the
vaccine, and none developed symptoms of the deadly disease.
The official refused to say when and where the human trials would be carried
out.
He said the vaccine could be produced in large quantities and had a longer
shelf life than other existing vaccines which could enable it to prevent an
outbreak more effectively.
"Our vaccine could be good for three years before it is injected into
people," the official said.
Meanwhile, another vaccine is ready for a second phase of human trials.
Zhong Nanshan, president of the Chinese Medical Association, said last month
that scientists in Beijing would test the effectiveness of the vaccine produced
by a Beijing-based company among volunteers aged 20 to 60.
Initial trials involving 36 volunteers in Beijing found antibodies against
the disease developed in all volunteers, without obvious side effects.
Scientists now want to sign up 300 volunteers for the second phase.
The new vaccine, produced by Beijing's Sinovac Biotech Co Ltd, must go
through three phases of trials before it can be licensed for public use.
SARS emerged in China in late 2002 and spread globally to infect more than
8,000 people and kill some 800 worldwide, including 349 in China.
cs/ag/jm

[waldron] 19/6/2005 11:23

BEIJING (AFX) - Chinese and European scientists conducting research in
eastern China have found that a medicine used to treat schizophrenia is
effective in treating patients with the SARS disease, Xinhua news agency
reported.
Scientists in eastern Hangzhou city found that cinanserin, used to treat
mental illness since the 1970s, can inhibit the coronavirus that causes Severe
Acute Respiratory Syndrome (SARS), Xinhua said.
The drug was identified as the only ready-to-use medicine among 15 possible
anti-SARS remedies recommended by scientists participating in the Sino-European
Project on SARS Diagnostics and Antivirals (SEPSDA), it said.
"The finding means that cinanserin could be directly prescribed to prevent
the SARS disease or treat SARS patients if the fatal epidemic mounts a
comeback," Peter Kristensen, an academic from Denmark's University of Aarhus,
was quoted as saying.
The 14 other possible remedies have to go through lengthy animal tests
before being used to treat human patients, said Kristensen, a participant of the
three-year SEPSDA program.
The program is funded by the European Union and involves eight Chinese and
European institutions. Launched in 2004, it aims to find 50 chemical compounds
to treat SARS.
Scientists working for the program also confirmed today the finding of two
homologous SARS coronaviruses in animals from the Netherlands and Hong Kong
respectively.
Both the newly found viruses and the formerly detected SARS virus were
variations of an ancient virus, which had been in animals for ages but remained
unidentified, said Rolf Hilgenfeld, a professor from Germany's University of
Luebeck.
The German scholar said other latent coronaviruses could pose dangers to
human beings as the SARS virus did.
"People should closely monitor such viruses and their variations to
effectively prevent them from endangering humans," said Hilgenfeld.
cs/br/rc

[grupo guitarlumber] 06/7/2004 06:45

SINGAPORE (AFX-ASIA) - Asian scientists are well-placed to take a leading
role in the global search for vaccines against emerging diseases after gaining
valuable experience from fighting recent health epidemics, a top World Health
Organisation (WHO) official said.
Fewer government restrictions on medical research compared with other parts
of the world also give the region's scientists an edge, David Heymann, WHO's
executive director of communicable diseases, said.
"SARS, avian flu, both of these diseases have shown that there is a place
for Asian scientists because the diseases are occurring in Asia," Heymann told
Agence France-Presse on the sidelines of a one-day medical symposium in
Singapore late yesterday.
"And Asian scientists were very active in both the SARS and the (bird)
influenza... there were some top notch scientists who have contributed most of
what we know and those scientists were Asians."
The Severe Acute Respiratory Syndrome (SARS) killed nearly 800 people last
year in an epidemic that mainly affected East Asia, while this year's regional
bird flu outbreak claimed 24 lives.
Heymann, whose task is to monitor communicable diseases, said it is
important that Asian scientists take a more active role in medical research
because their counterparts elsewhere are hindered by tougher regulations.
"Asia has many, many capable scientists and they must now begin to play a
role in world research and development because in (other) parts of the world,
research has become very restrictive," he said.
Heymann cited an inability to use stem cells, other heavy regulatory
processes and high research and development costs as critical factors hampering
scientists elsewhere.
"So Asia where the cost is less, where regulation might be a different
approach, has to play its role," he said.
Heymann believes Hong Kong and Singapore, which were among the worst
affected nations from the SARS outbreak, particularly have the potential to make
their mark.
"Hong Kong has excellent research and development, especially research,
capabilities in identifying and responding to new diseases," he said.
"Singapore also has great capacities and great potential through things such
as the NITD," he said, referring to the Novartis Institute of Tropical Diseases
research facility that opened yesterday.
Heymann said the NITD, a joint collaboration between Swiss pharmaceutical
giant Novartis and the Singapore government, could pave the way for new,
low-cost drugs to treat tropical diseases such as tuberculosis.
"The NITD is very important because it has all of the information that
Novartis has and some of Novartis partner companies," he said.
"So it can use that information, those products that might be on the shelf,
to do screening to see if they are effective for diseases that they are
interested in.
"So it takes the private sector information and puts it into a public sector
not-for-profit foundation or institute and it cuts the cost that they need to
spend in developing the new goods."
Sixty-four researchers from around the world will work at the not-for-profit
Novartis institute, which is initially aiming to find cheap treatments for
dengue fever and drug-resistant tuberculosis.
There is currently no drug that can treat dengue fever, which infects as
many as 50 million people annually, mostly in the developing world.
bh/kma/bjn/rc

[maywillow] 25/6/2004 08:58

Nasal vaccine works against Sars


The scientists have three approaches to beating the virus
US scientists have successfully developed a nasal spray version of Sars vaccine that works in monkeys.
This is the third Sars vaccine made by the National Institute of Allergy and Infectious Diseases.

The previous two required two doses to work, had to be injected under the skin and had only been tested in rats.

The new nasal vaccine needs only one dose and is delivered directly into the respiratory tract where Sars attacks, they say in the Lancet.

The NIAID researchers are hopeful that a similar nasal vaccine against Sars could be developed for humans.

With more research, we hope to develop a vaccine based on this approach that could be used to rapidly immunise first responders and other medical personnel

Dr Brian Murphy, lead researcher at the NIAID

Like the previous two, the newest vaccine uses a small piece of the virus's DNA to stimulate the body's immune system to mount a protective response.

They took a small piece of DNA from the Sars virus that codes for a protein normally found on its outer surface.

They then put the piece of Sars DNA into a weakened version of a virus that causes respiratory diseases like pneumonia in humans.

Direct delivery

This virus carried the Sars DNA directly into the respiratory tract.

Tests in monkeys showed the vaccine provided protection against Sars without causing infection itself.

Lead researcher Dr Brian Murphy said: "This study shows that delivering the vaccine directly to the respiratory tract can effectively protect primates from Sars.

"With more research, we hope to develop a vaccine based on this approach that could be used to rapidly immunise first responders and other medical personnel, helping them control a potential outbreak," he said.

Dr Murphy says the vaccine in its current form would be most effective in young children. This is because most adults already have some immunity against the common viruses that cause pneumonia.

"In the long run, we want to establish a weakened respiratory virus vector that all people are susceptible to," he said.

Professor Maria Zambon of the Health Protection Agency said: "This represents a significant advance in the fight against Sars, but it's overall importance will be judged against time, when further human trials have taken place.

"The development of new vaccines against any infectious disease usually involves a variety of approaches and methods of delivery."

[grupo guitarlumber] 26/5/2004 09:48

BEIJING (AFX-ASIA) - China has published the initial results of the world's
first clinical testing of a SARS vaccine, saying the four human guinea pigs were
doing fine.
Seventy-two hours after receiving their injections, the four -- three men
and one woman -- had shown no adverse reactions, Xinhua news agency reported.
However, there is more than six months to go before the experiment is
completely over.
It could take even longer -- probably years -- before a SARS vaccine is
properly developed and enters into mass production.
The four are the first out of 36 volunteers who have agreed to participate
in the test, jointly developed by China's Science and Technology Ministry and
the Beijing Kexing Vaccine Company.
Severe Acute Respiratory Syndrome originally emerged in south China at the
end of 2002, and eventually struck 32 countries, infecting some 8,000 people and
killing nearly 800 before subsiding.
China was worst hit, accounting for 349 deaths and 5,327 infections.
Since China was declared SARS free last July, four new confirmed cases were
reported this winter, and nine other cases in a recent outbreak this spring, all
linked to a Beijing lab, including one victim who later died.
ph/mp/jah/wpf

[waldron] 22/4/2004 08:32

PENANG, Malaysia (AFX-ASIA) - Deputy Prime Minister Najib Razak said a
recent survey showed that the impact of SARS so far on Asian economies was 10.6
bln usd and could eventually total as much as 50 bln usd.
He made the remarks while opening a conference of health ministers from the
10-member Association of Southeast Asian Nations (ASEAN), which aims to forge a
common action plan against epidemics.
Najib did not give details, but warned that Asia faces the threat of more
deadly epidemics such as the Severe Acute Respiratory Syndrome (SARS).
"New diseases like the bird flu and SARS have been emerging at the rate of
one per year and the trend is certain to continue," he said.
SARS devastated the region's vital travel and tourism industries when it
killed nearly 800 people and infected more than 8,000 in more than 30 countries
last year, mostly in Asia.
Bird flu affected some 10 Asian nations, killed at least 23 people and led
to the culling of millions of chickens.
Najib said the epidemics had shown that pathogens jumped species barriers
and that the high mobility of people in the region meant no country could
insulate itself.
"The need to cooperate cannot be over emphasized. These diseases would not
be the last of their kind to spread rapidly. The world it seems shall never be
free from the threat of epidemics," he said.
A rapid and effective regional response mechanism would contribute to the
ability to combat future outbreaks, he said.
With the theme "Health Without Frontiers", the health ministers plan to
adopt a blueprint on coordinating their efforts over surveillance and emergency
responses to health crises.
Health ministers from Singapore and Indonesia echoed Najib's fears and
voiced support for a common plan of action.
"ASEAN went through a difficult period with SARS. At that time we had to
improvise and see how to cooperate effectively," Singapore's Khaw Boon Wan told
reporters.
"With the SARS crisis at the moment over, it is a good time to consolidate
and institutionalise the various cooperation plans."
These could include information sharing, transparency over outbreaks and
taking quick action to contain them, he said.
"Nature has a way to surprise us. Just as we were all geared up for winter
SARS, instead we had the bird flu," he said.
Indonesia's Achmad Sujudi said ASEAN countries need to ensure close
cooperation.
"This commitment from all countries is vital. We will have a common
blueprint to follow after this meeting," he said.
Achmad said Indonesia still faces the threat of bird flu and the impact on
its poultry industry had been significant.
Tomorrow the 10 ASEAN members will be joined by their counterparts from
China, Japan and South Korea in a first cooperative effort to tackle the
region's health problems.
The ministers will also discuss efforts to reverse the spread of AIDS in the
region.
jsm/lb/rcw/rc

[crystalclear] 24/2/2004 11:37

Are SARS and bird flu actually different?
Didn't the WHO just agree with the Chinese to call it something else to avoid hysteria?

And what is the long term beneficial effect of finding cures to these things on a planet where 800 million people go to sleep hungry?

[ariane] 23/2/2004 15:00

AMSTERDAM (AFX) - A Dutch virologist says a known hepatitis and cancer drug
works as a preventative treatment against SARS in monkeys and is likely to be
effective in humans as well, daily De Volkskrant reported, citing the
researcher.
Professor Ab Osterhaus of the National Influenza Centre, which works under
the auspices of the World Health Organisation, says he found that the SARS virus
propagated much more slowly in monkeys injected with pegylated interferon-alpha
than in animalsthat had not been given the substance.
Any damage to the injected monkeys' lungs was also far less extensive, he
said.
The drug is already being used as a treatment for hepatitis C and some forms
of cancer in humans.
Osterhaus' research will be published in the Nature Medicine journal in
March, the report said.
The drug is yet to be tested as a SARS treatment for people, but Osterhaus
was optimistic it would be effective. "It looks as if the way the (SARS) virus
spreads in monkeys is similar to humans," he said.
It could already be used to offer some protection for health workers in the
event of a SARS outbreak, he added.
[e-mail]
pav/jlw

[hyper al] 24/1/2004 08:52

CHAMBEAJ

Sounds like a good idea, as it will take at least 4 months to create a vaccine once the strain has mutated to the Human/Human form and probably the same number of months to produce the quantities that will be required.

EVERYONE

I created a new thread about a week ago, for posts concerning Avian Flu.
If you don't mind could you post Avian Flu news on that thread at



Regards

Hyper Al

[chambeaj] 24/1/2004 00:07

Expert warns Government to stockpile anti-viral drugs to halt avian flu pandemic

[hyper al] 23/1/2004 08:33

CHAMBEAJ

These articles don't mention Human to Human transmission of bird flu. If they did, panic!

[chambeaj] 23/1/2004 08:13

'Chicken flu poses threat to humanity'


Chicken 'flu poses a "massively frightening" potential threat to humanity, a leading medical journal said.

Thailand: Bird flu has leapt to humans

[chambeaj] 14/1/2004 07:23

Bird flu 'could be worse than Sars'